US gov­ern­ment chal­lenges ju­ry de­ci­sion in Gilead HIV patent tri­al

The US gov­ern­ment has asked a Delaware fed­er­al court to re­verse a re­cent ju­ry de­ci­sion fa­vor­ing Gilead in the par­ties’ long-run­ning HIV drug patent bat­tle.

The case traces back to a com­plaint filed in 2019 al­leg­ing Gilead’s grow­ing HIV pre-ex­po­sure pro­phy­lax­is (PrEP) fran­chise ben­e­fit­ed from the CDC’s “ground­break­ing PrEP work” fund­ed by “hun­dreds of mil­lions of tax­pay­er dol­lars.” The phar­ma gi­ant’s Tru­va­da and De­scovy were ini­tial­ly ap­proved for the treat­ment of HIV in 2004 and 2016, re­spec­tive­ly, but each won ap­provals years lat­er in the pre­ven­tive set­ting.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA